INJECTAFER- ferric carboxymaltose injection injection, solution INJECTAFER- ferric carboxymaltose injection, solution États-Unis - anglais - NLM (National Library of Medicine)

injectafer- ferric carboxymaltose injection injection, solution injectafer- ferric carboxymaltose injection, solution

american regent, inc. - ferric carboxymaltose (unii: 6897gxd6oe) (ferric cation - unii:91o4lml611) - ferric cation 50 mg in 1 ml - injectafer is indicated for the treatment of: •     iron deficiency anemia (ida) in: - adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. - adult patients who have non-dialysis dependent chronic kidney disease. adult patients who have non-dialysis dependent chronic kidney disease. •     iron deficiency in adult patients with heart failure and new york heart association class ii/iii to improve exercise capacity. injectafer is contraindicated in patients with a history of hypersensitivity to injectafer or any of its components [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [ see warnings and precautions (5.1)], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant wome

MEFENAMIC ACID- mefenamic acid capsule États-Unis - anglais - NLM (National Library of Medicine)

mefenamic acid- mefenamic acid capsule

breckenridge pharmaceutical, inc. - mefenamic acid (unii: 367589pj2c) (mefenamic acid - unii:367589pj2c) - mefenamic acid 250 mg - carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation ). mefenamic acid is indicated: - for relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days). - for treatment of primary dysmenorrhea. mefenamic acid is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions) . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients (see warnings; anaphylactic reaction, exacerbation of asth

Ferric carboxymaltose 50 mg iron/ml solution for injection/infusion Irlande - anglais - HPRA (Health Products Regulatory Authority)

ferric carboxymaltose 50 mg iron/ml solution for injection/infusion

rowex ltd - ferric carboxymaltose - solution for injection/infusion - iron, parenteral preparations

Monoferric 100 mg/ml inj./inf. sol. i.v. amp. Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

monoferric 100 mg/ml inj./inf. sol. i.v. amp.

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Monoferric 100 mg/ml inj./inf. sol. i.v. vial Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

monoferric 100 mg/ml inj./inf. sol. i.v. vial

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Monoferric 100 mg/ml inj./inf. sol. i.v. amp. Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

monoferric 100 mg/ml inj./inf. sol. i.v. amp.

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Monoferric 100 mg/ml inj./inf. sol. i.v. vial Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

monoferric 100 mg/ml inj./inf. sol. i.v. vial

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Monoferric 100 mg/ml inj./inf. sol. i.v. amp. Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

monoferric 100 mg/ml inj./inf. sol. i.v. amp.

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Monoferric 100 mg/ml inj./inf. sol. i.v. vial Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

monoferric 100 mg/ml inj./inf. sol. i.v. vial

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Monoferric 100 mg/ml inj./inf. sol. i.v. amp. Belgique - anglais - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

monoferric 100 mg/ml inj./inf. sol. i.v. amp.

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations